107 related articles for article (PubMed ID: 22118776)
1. Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types.
Bae S; Ma K; Kim TH; Lee ES; Oh KT; Park ES; Lee KC; Youn YS
Biomaterials; 2012 Feb; 33(5):1536-46. PubMed ID: 22118776
[TBL] [Abstract][Full Text] [Related]
2. TRAIL acts synergistically with iron oxide nanocluster-mediated magneto- and photothermia.
Belkahla H; Mazarío E; Sangnier AP; Lomas JS; Gharbi T; Ammar S; Micheau O; Wilhelm C; Hémadi M
Theranostics; 2019; 9(20):5924-5936. PubMed ID: 31534529
[TBL] [Abstract][Full Text] [Related]
3. Probing and Enhancing Ligand-Mediated Active Targeting of Tumors Using Sub-5 nm Ultrafine Iron Oxide Nanoparticles.
Xu Y; Wu H; Huang J; Qian W; Martinson DE; Ji B; Li Y; Wang YA; Yang L; Mao H
Theranostics; 2020; 10(6):2479-2494. PubMed ID: 32194814
[No Abstract] [Full Text] [Related]
4. A redox-sensitive micelle-like nanoparticle self-assembled from amphiphilic adriamycin-human serum albumin conjugates for tumor targeted therapy.
Chen L; Chen F; Zhao M; Zhu X; Ke C; Yu J; Yan Z; Zhang F; Sun Y; Chen D; Jiang C; Zhao X; Gao Y; Guo S; Li W
Biomed Res Int; 2015; 2015():987404. PubMed ID: 26075280
[TBL] [Abstract][Full Text] [Related]
5. Effect of pullulan nanoparticle surface charges on HSA complexation and drug release behavior of HSA-bound nanoparticles.
Tao X; Zhang Q; Ling K; Chen Y; Yang W; Gao F; Shi G
PLoS One; 2012; 7(11):e49304. PubMed ID: 23166632
[TBL] [Abstract][Full Text] [Related]
6. Targeting tumour-initiating cells with TRAIL based combination therapy ensures complete and lasting eradication of multiple myeloma tumours in vivo.
Vitovski S; Chantry AD; Lawson MA; Croucher PI
PLoS One; 2012; 7(5):e35830. PubMed ID: 22615740
[TBL] [Abstract][Full Text] [Related]
7. Biomacromolecules as carriers in drug delivery and tissue engineering.
Zhang Y; Sun T; Jiang C
Acta Pharm Sin B; 2018 Jan; 8(1):34-50. PubMed ID: 29872621
[TBL] [Abstract][Full Text] [Related]
8. Hydroxyurea-Loaded Albumin Nanoparticles: Preparation, Characterization, and In Vitro Studies.
Tazhbayev Y; Mukashev O; Burkeev M; Kreuter J
Pharmaceutics; 2019 Aug; 11(8):. PubMed ID: 31409024
[TBL] [Abstract][Full Text] [Related]
9. Human Serum Albumin-Platinum(II) Agent Nanoparticles Inhibit Tumor Growth Through Multimodal Action Against the Tumor Microenvironment.
Xu S; Luo W; Zhu M; Zhao L; Gao L; Liang H; Zhang Z; Yang F
Mol Pharm; 2024 Jan; 21(1):346-357. PubMed ID: 38015620
[TBL] [Abstract][Full Text] [Related]
10. Heparin-Coated Albumin Nanoparticles for Drug Combination in Targeting Inflamed Intestine.
Zhang S; Cho WJ; Jin AT; Kok LY; Shi Y; Heller DE; Lee YL; Zhou Y; Xie X; Korzenik JR; Lennerz JK; Traverso G
Adv Healthc Mater; 2020 Aug; 9(16):e2000536. PubMed ID: 32597571
[TBL] [Abstract][Full Text] [Related]
11. Human Serum Albumin Nanoparticles as a Carrier of 20(
Liu L; Yang B; Yuan H; Yu N; Feng Y; Zhang Y; Yin T; He H; Gou J; Tang X
Mol Pharm; 2023 Oct; 20(10):5125-5134. PubMed ID: 37647098
[TBL] [Abstract][Full Text] [Related]
12. Albumin-Modified Melanin-Silica Hybrid Nanoparticles Target Breast Cancer Cells via a SPARC-Dependent Mechanism.
Sanità G; Armanetti P; Silvestri B; Carrese B; Calì G; Pota G; Pezzella A; d'Ischia M; Luciani G; Menichetti L; Lamberti A
Front Bioeng Biotechnol; 2020; 8():765. PubMed ID: 32733871
[TBL] [Abstract][Full Text] [Related]
13. Improved Targeting and Safety of Doxorubicin through a Novel Albumin Binding Prodrug Approach.
Liu Y; Corrales-Guerrero S; Kuo JC; Robb R; Nagy G; Cui T; Lee RJ; Williams TM
ACS Omega; 2024 Jan; 9(1):977-987. PubMed ID: 38222540
[TBL] [Abstract][Full Text] [Related]
14. Development of doxorubicin loading platform based albumin-sporopollenin as drug carrier.
Maltas E; Gubbuk IH; Yildiz S
Biochem Biophys Rep; 2016 Sep; 7():201-205. PubMed ID: 28955907
[TBL] [Abstract][Full Text] [Related]
15. Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer.
Choi SH; Byeon HJ; Choi JS; Thao L; Kim I; Lee ES; Shin BS; Lee KC; Youn YS
J Control Release; 2015 Jan; 197():199-207. PubMed ID: 25445703
[TBL] [Abstract][Full Text] [Related]
16. Albumin nanoparticles with predictable size by desolvation procedure.
Storp Bv; Engel A; Boeker A; Ploeger M; Langer K
J Microencapsul; 2012; 29(2):138-46. PubMed ID: 22329480
[TBL] [Abstract][Full Text] [Related]
17. Advances in Receptor-Mediated, Tumor-Targeted Drug Delivery.
Large DE; Soucy JR; Hebert J; Auguste DT
Adv Ther (Weinh); 2019 Jan; 2(1):. PubMed ID: 38699509
[TBL] [Abstract][Full Text] [Related]
18. The Role of TRAIL in Apoptosis and Immunosurveillance in Cancer.
Pimentel JM; Zhou JY; Wu GS
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345089
[TBL] [Abstract][Full Text] [Related]
19. Formation of Protein Nanoparticles in Microdroplet Flow Reactors.
Zhang Q; Toprakcioglu Z; Jayaram AK; Guo G; Wang X; Knowles TPJ
ACS Nano; 2023 Jun; 17(12):11335-11344. PubMed ID: 37306477
[TBL] [Abstract][Full Text] [Related]
20. TRAIL mediated apoptosis ruling and anticancer trigger by fine-tuned nano spheres of Fagonia cretica methanolic extracts as novel cancer regime.
Ahmed W; Mansoor Q; Ahmad MS; Zainab T; Shah MA
Sci Rep; 2023 Jan; 13(1):671. PubMed ID: 36635434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
